Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

医学 蛋白尿 临床终点 内科学 肾病 肾功能 安慰剂 肾脏疾病 临床试验 胃肠病学 病理 内分泌学 糖尿病 替代医学
作者
Richard A. Lafayette,Jens Kristensen,Andrew Stone,Jürgen Floege,Vladimı́r Tesař,Hernán Trimarchi,Hong Zhang,Necmi Eren,Alexander Paliege,Heather N. Reich,Brad H. Rovin,Jonathan Barratt
出处
期刊:The Lancet [Elsevier]
卷期号:402 (10405): 859-870 被引量:73
标识
DOI:10.1016/s0140-6736(23)01554-4
摘要

IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is a novel, oral, targeted-release formulation of budesonide designed to act at the gut mucosal level. We present findings from the 2-year, phase 3 NefIgArd trial of Nefecon in patients with IgA nephropathy.In this phase 3, multicentre, randomised, double-blind, placebo-controlled trial, adult patients (aged ≥18 years) with primary IgA nephropathy, estimated glomerular filtration rate (eGFR) 35-90 mL/min per 1·73 m2, and persistent proteinuria (urine protein-creatinine ratio ≥0·8 g/g or proteinuria ≥1 g/24 h) despite optimised renin-angiotensin system blockade were enrolled at 132 hospital-based clinical sites in 20 countries worldwide. Patients were randomly assigned (1:1) to receive 16 mg/day oral capsules of Nefecon or matching placebo for 9 months, followed by a 15-month observational follow-up period off study drug. Randomisation via an interactive response technology system was stratified according to baseline proteinuria (<2 or ≥2 g/24 h), baseline eGFR (<60 or ≥60 mL/min per 1·73 m2), and region (Asia-Pacific, Europe, North America, or South America). Patients, investigators, and site staff were masked to treatment assignment throughout the 2-year trial. Optimised supportive care was also continued throughout the trial. The primary efficacy endpoint was time-weighted average of eGFR over 2 years. Efficacy and safety analyses were done in the full analysis set (ie, all randomly assigned patients). The trial was registered on ClinicalTrials.gov, NCT03643965, and is completed.Patients were recruited to the NefIgArd trial between Sept 5, 2018, and Jan 20, 2021, with 364 patients (182 per treatment group) randomly assigned in the full analysis set. 240 (66%) patients were men and 124 (34%) were women, and 275 (76%) identified as White. The time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit with Nefecon versus placebo (difference 5·05 mL/min per 1·73 m2 [95% CI 3·24 to 7·38], p<0·0001), with a time-weighted average change of -2·47 mL/min per 1·73 m2 (95% CI -3·88 to -1·02) reported with Nefecon and -7·52 mL/min per 1·73 m2 (-8·83 to -6·18) reported with placebo. The most commonly reported treatment-emergent adverse events during treatment with Nefecon were peripheral oedema (31 [17%] patients, vs placebo, seven [4%] patients), hypertension (22 [12%] vs six [3%]), muscle spasms (22 [12%] vs seven [4%]), acne (20 [11%] vs two [1%]), and headache (19 [10%] vs 14 [8%]). No treatment-related deaths were reported.A 9-month treatment period with Nefecon provided a clinically relevant reduction in eGFR decline and a durable reduction in proteinuria versus placebo, providing support for a disease-modifying effect in patients with IgA nephropathy. Nefecon was also well tolerated, with a safety profile as expected for a locally acting oral budesonide product.Calliditas Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助夏青荷采纳,获得10
2秒前
passion完成签到,获得积分10
2秒前
3秒前
小小果妈发布了新的文献求助10
4秒前
开朗黑猫完成签到,获得积分10
6秒前
无奈柚子发布了新的文献求助10
6秒前
6秒前
Lucas应助太清采纳,获得10
7秒前
Zjin宇完成签到,获得积分10
8秒前
8秒前
不配.应助shaco采纳,获得10
8秒前
Owen应助小小果妈采纳,获得10
11秒前
李嶍烨发布了新的文献求助10
12秒前
hcq发布了新的文献求助10
12秒前
12秒前
whuhustwit发布了新的文献求助10
12秒前
无奈柚子完成签到,获得积分10
13秒前
关七应助ren采纳,获得30
14秒前
林夕完成签到 ,获得积分10
15秒前
16秒前
我是老大应助Layli采纳,获得10
18秒前
Shxu完成签到,获得积分10
21秒前
马鑫麟发布了新的文献求助10
22秒前
23秒前
xyz发布了新的文献求助10
23秒前
24秒前
小蘑菇应助阿良采纳,获得10
27秒前
深情安青应助听风说情话采纳,获得10
28秒前
勤恳的磬发布了新的文献求助10
28秒前
29秒前
闫霄溯完成签到,获得积分10
29秒前
可爱的函函应助xyz采纳,获得10
29秒前
Billy发布了新的文献求助10
30秒前
40873完成签到,获得积分10
30秒前
伊麦香城发布了新的文献求助10
31秒前
33秒前
烟花应助开放觅夏采纳,获得30
34秒前
36秒前
38秒前
乐乐应助清脆的乌冬面采纳,获得10
38秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3136151
求助须知:如何正确求助?哪些是违规求助? 2787065
关于积分的说明 7780419
捐赠科研通 2443217
什么是DOI,文献DOI怎么找? 1298945
科研通“疑难数据库(出版商)”最低求助积分说明 625294
版权声明 600870